Pegasus Laboratories' Liavium-CA1 Gains Conditional FDA Approval for Canine Pain Management

Liavium-CA1: A Game Changer in Canine Neuropathic Pain Management

On May 18, 2026, Pegasus Laboratories, Inc. made a significant advancement in veterinary medicine by receiving conditional approval from the U.S. Food and Drug Administration (FDA) for its new product, Liavium-CA1. This innovative chewable tablet contains pregabalin, a first-in-class therapy specifically designed for dogs suffering from Chiari-like malformation and syringomyelia (CM/SM), a serious neurological condition often overlooked by many veterinarians.

Understanding CM/SM and Its Impact on Dogs

Chiari-like malformation and syringomyelia are painful conditions that result from structural abnormalities in a dog's skull and spine. These ailments can lead to chronic and debilitating pain, significantly impacting the quality of life for affected dogs. Common symptoms include phantom scratching, vocalizations, and hypersensitivity around the head and neck—often misdiagnosed as anxiety or signs of aging. Unfortunately, these conditions predominantly affect small and toy breeds, particularly the Cavalier King Charles Spaniel, which contributes to a misconception that they are merely behavioral issues.

Veterinarians have historically faced challenges in effectively managing neuropathic pain associated with these conditions. However, the introduction of Liavium-CA1 shifts the paradigm by offering a dedicated treatment option that addresses the specific needs of these dogs.

The Significance of Liavium-CA1

Dr. Heather Davis, Senior Director of Medical Affairs at Pegasus, emphasized the importance of this product, stating, "Liavium-CA1 signifies a turning point in canine pain management by providing veterinarians a first-of-its-kind option to effectively manage neuropathic pain." The approval is a reflection of Pegasus' commitment to innovative solutions that cater to unmet needs in animal health, thereby enhancing the lives of pets and supporting their care providers.

The conditional approval of this medication does not merely serve to bring a new product to the market; it also allows veterinarians to begin incorporating it into their practices while ongoing studies continue to validate its effectiveness. A pivotal clinical trial is currently underway across various sites in the United States, bolstering the data required for full FDA approval.

Product Availability and Dosage

Liavium-CA1 will be sold in three strengths: 30 mg, 90 mg, and 180 mg, all beef-flavored to ensure palatable administration for dogs weighing between 6.6 to 50 pounds. The 90 mg tablet is designed to be scored, allowing for easier dosage adjustments as needed. As a Schedule V controlled substance, Liavium-CA1 is subject to strict regulations regarding its prescription and dispensing, ensuring that it is used safely and effectively.

Safety Considerations

While Liavium-CA1 offers promising benefits, it is essential to be aware of potential adverse reactions associated with pregabalin. These may include drowsiness, increased appetite, decreased activity, and variations in water intake, among others. The medication has not been thoroughly studied in dogs with renal issues, or those that are pregnant or breeding, establishing a need for close monitoring and consideration during prescribing.

Future Developments from Pegasus

Founded in 1986, Pegasus Laboratories has established itself as a premier organization dedicated to developing specialized pharmaceutical solutions for animal health. Their focus on treating chronic conditions in pets, including cats and horses, is indicative of their commitment to advancing veterinary care. With the acquisition of TriviumVet in 2025, Pegasus is now better positioned to innovate in areas of unmet needs, ensuring that more options are available for veterinarians and their patients.

Conclusion

The conditional approval of Liavium-CA1 marks a significant milestone in veterinary medicine and offers newfound hope for dogs suffering from CM/SM. This innovative medication not only addresses a critical health challenge but also empowers veterinarians with tools to enhance the quality of life for countless dogs. As research continues, the veterinary community eagerly anticipates further developments around this promising treatment option.